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ABSTRACT
Dibenzoylmethane (DBM), a curcumin-related β-diketone analogue, has been reported to exhibit a remarkable inhibitory effect on
7,12-dimethylbenz[a]anthracene (DMBA)-induced mammary tumorigenesis in Sencar mice. Investigation of the underlying mechanisms of DBM in the prevention of mammary tumorigenesis implied its role as an effector of Phase I enzymatic system. In this report,
the metabolic fate of DBM by NADPH-dependent cytochrome P450 enzymes in mouse liver microsomes was demonstrated. Isolation
of the major reductive metabolites of DBM (DBMH2), together with several minor metabolites identified by NMR, GC and LC-MS,
explained the potential role of DBM as a modulator of the cytochrome P450 reductase that is required for the function of oxidase to
metabolize DMBA. These might also contribute to the result of the inhibitory effect of DBM on DMBA-induced mouse mammary
tumorigenesis.
Key words: dibenzoylmethane, 7,12-dimethylbenz[a]anthracene, reductive metabolite, mouse liver microsomes, NADPH-dependent
cytochrome P450 enzymes, mammary tumorigenesis

INTRODUCTION
Curcumin, the major yellow constituent in turmeric
(the ground rhizome of Curcuma longa Linn) has been used
for the treatment of inflammatory-related diseases in traditional medicine. Several studies have shown that dietary
curcumin inhibits certain chemically-induced tumorigenesis
in animal models, mainly due to its strong antioxidant and
antiinflammatory activities(1). Despite of the broad chemopreventive effects on various cancers, its poor absorption
and bioavailability precluded curcumin from inhibiting
mammary tumor formation (2-4) . However, dibenzoylmethane (DBM), a β-diketone structural analogue of
curcumin, has received attention in recent years because of
its potent anticarcinogenic activity against 7,12-dimethylbenz[a]anthracene(DMBA)-induced mammary tumorigenesis tested in both mice and rats(4,5).
DMBA, an effective carcinogenic initiator, is metabolically activated by cytochrome P450 oxidase to electrophilic diol-epoxide intermediates, which subsequently
interact with DNA to form DMBA-DNA adducts(8,13). In
our previous in-vivo and in-vitro studies, DBM inhibited
DMBA metabolism and formation of DMBA-DNA adducts
in a dose-dependent manner (14,15). Investigation of the
underlying mechanism regarding the involvement of β* Author for correspondence. Tel: +732-932-9611 ext. 235;
Fax: +732-932-6776; E-mail: ho@aesop.rutgers.edu

diketone moiety of DBM on mammary tumorigenesis is
important. The β-diketone functionality in curcumin has
been showed to exhibit antioxidative activity on tert-butylhydroperoxide-induced lipid peroxidation of erythrocyte
membrane ghosts(6). Talalay also reported the potency of
DBM as an inducer of Phase II detoxification enzymes, in
part due to the β-diketone functionality(7). However, not
any report published so far has concerned the influence of
the β-diketone group on cytochrome P450 Phase I metabolizing enzymes, since DMBA needs to be oxidatively
metabolized to bioactive carcinogen(8).
In the present study, we examined the metabolic fate of
DBM by NADPH-dependent cytochrome P450 enzymes in
mouse liver microsomes. In vivo, curcumin with a β-diketone moiety has been proved to be transformed through
reduction as well as glucuronidation to tetrahydrocurcumin
found in rat bile excretion(3). The finding of a major reductive DBM metabolite in β-diketone moiety in vitro may
provide partially the explanation from chemical aspects on
the inhibitory of DBM on DMBA-induced tumorigenesis.

MATERIALS AND METHODS
I. Chemicals
Dibenzoylmethane, glucose-6-phosphate, glucose-6-
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phosphate dehydrogenase, NADPH, TLC plate (250 µm
thickness, 2-25 µm particle size), silica gel (70-230 mesh)
were purchased from Sigma Chemical Co. (St. Louis, MO,
USA). CD3OD was purchased from Aldrich (Milwaukee,
WI). All solvents (HPLC grade) were purchased from
Fisher Scientific Co. (Springfield, NJ, USA).
II. Preparation of Mouse Liver Microsomes
Seven to 8 weeks old female Sencar mice from
Charles River Laboratories (Wilmington, MA, USA) were
fed on an AIN 76A diet (control group) or 1% DBM diet
for 2-3 weeks. The mice were killed by decapitation and
livers were removed, rinsed in cold saline to remove excess
blood. The livers were then homogenized in 2 volumes
(w/v) of 0.05 M Tris-HCl (pH 7.5 at 4˚C), 0.15 M KCl and
the microsomal fraction was isolated by differential centrifugation. Briefly, the homogenates were centrifuged at
11,000×g for 20 min; the supernatant fraction was re-centrifuged for 1 hr at 105,000×g. The microsomal fraction
was suspended in 0.25 M sucrose and stored in small
aliquots at -80˚C. The concentration of protein was determined by a Bio-Rad protein assay kit with BSA as a
standard.
III. Incubation of DBM with Mouse Liver Microsomes

metabolite were collected and concentrated to afford a
colorless liquid (about 20% yield). Structural confirmation
of the major metabolite was achieved by NMR and identified as 1,3-diphenyl-3-hydroxyl-1-propanone. 1H-NMR
(200 MHz, CD3OD): 7.98 (2H, d, J = 7.2 Hz, H-2’), 7.607.25 (8H, m, H-2”, H-3’, H-3”, H-4’, H-4”), 5.31 (1H, dd,
J = 8.4, 4.8 Hz, H-3), 3.52 (1H, dd, J = 8.4,16 Hz, H-2a),
3.29 (1H, dd, J = 4.8, 16 Hz, H-2b).
V. Analysis of the Minor DBM Metabolites by GC-MS and
LC-MS
Analysis of the minor metabolites of DBM was
achieved by the GC-LC and LC-MS system consisting of
Hewlett-Packard 5989A mass spectrometer interfaced with
a 5890 Series II gas chromatograph or HP59980 particle
beam. The gas chromatograph was equipped with a 30 m
DB-1 capillary GC column ( 0.32 mm I.D., 0.3 µm film
thickness) and a MS detector. The injector port and
detector temperatures were 250˚C and 280˚C, respectively.
The column temperature was programmed from 70˚C to
250˚C at a rate of 4˚C/min with helium as the carrier gas.
Injections were made in splitless mode at a column head
pressure of 14 psi. The retention time and mass fragmentation pattern for each metabolite peak were compared
with those of standards searched by GC-MS spectral
database (Wiley138 library). LC-MS was performed by
using a Supelco reverse-phase column (15 cm × 2 mm).
An isocratic mobile phase consisting of acetonitrile/water
(7/3) at a flow rate of 0.4 mL/min was used. Chemical
ionization spectra were obtained using ammonium as the
reagent gas.

The reaction mixture contained 0.5 mg liver microsomes, 100 mM KH2PO4 (pH 7.4), 5 mM MgCl2, 0.1 mM
EDTA, and a NADPH regeneration system, which consisted
of 20 mM glucose-6-phosphate, 1 unit G-6-P dehydrogenase, 5 mM NADPH and 100 µM of DBM in a final
volume of 100 mL. The reaction was incubated at 37˚C for
several hours. After the incubation, the reaction was
stopped by adding 1 mL of 5 N HCl and extracted with 2-3
volume folds of ethyl acetate. The organic layer was dried
over MgSO4, concentrated under reduced pressure to about
200 µL and then subjected to TLC and HPLC analysis.

I. Identification of A Major Metabolite of DBM from
Incubation with Mouse Liver Microsomes In Vitro

IV. Procedure for Separation and Identification of Major
DBM Metabolite

The HPLC profile for DBM metabolism in a NADPHdependent mix function oxidase system by liver micro-

Analysis of DBM metabolites was performed by using
a Varian 5000 HPLC system equipped with a Varian 2050
detector and a normal phase column (α-chrom, 3 mm × 25
cm, Upchurch Scientific, Inc.) The solvents used for separation of DBM and its metabolites consisted of n-hexane/
ethyl acetate. The solvent gradient programmed in HPLC
was as follows: 0 min isocratic at 100/0; 5 min of gradient
to 95/5; 1 min of gradient to 92/8; 14 min of gradient to
80/20; 5 min of gradient to 70/30; 5 min of gradient to
60/40. The HPLC metabolite peaks were detected by UV
at 265 nm. Isolation of the major metabolite was
performed by silica gel column chromatography using
n-hexane/ethyl acetate (80/20) as eluent. The spots shown
on TLC corresponded to DBM (Rf 0.9), major product (Rf
0.5) and minor products (Rf 0.1). The fractions with major

RESULTS AND DISCUSSION

OH

O
H3CO

OCH3

OH

OH
Curcumin

O

OH

Dibenzoylmethane

Figure 1. Structures of curcumin and dibenzoylmethane.
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Table 1. Identification of the metabolites of DBM by GC-MS and LC-MS
Metabolite
Method
Retention time (min)
Characteristic MS fragments
1,3-diphenyl-3LC-MS
0.81
244 (M+18), 227 (M+1),
226 (M), 209 (M-17)
hydroxyl-1-proopanonea
Benzoic acid
GC-MS
16.71 (trace)
122, 106, 105 (base peak), 77, 51
LC-MS
0.47
123 (M+1)
Chalcone
GC-MS
37.66
208, 207 (base peak), 131, 105, 103, 77
Dihydro-chalcone
GC-MS
38.92
210, 105, 104 (base peak), 79, 77
The condition for incubation was the same as described in assay for in-vitro DMBA metabolism except that DBM (200 µM) without DMBA
was the only substrate added to the reaction. The reaction mix was subjected to GC-MS and LC-MS analysis as described in “MATERIALS
AND METHODS”. The retention time and mass fragmentation pattern for each metabolite peak in GC-MS spectra were compared with those
of reference standards searched by GC-MS spectral database (Wiley138 library).
a
The reductive metabolite was further characterized by NMR and compared with synthesized authentic standard.

34.28
35.14

26.63
14.89

S. M.

14.32

Absorbance at 265 nm

DBMH2
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Figure 2. HPLC profile for analysis of metabolites of DBM by
mouse liver microsomes. Seven to 8 weeks old female Sencar mice
were fed with AIN 76A diet or 1% DBM diet for 2-3 weeks and the
mice were sacrificed for the preparation of liver microsomes.
Reaction mixture consisted of 200 mM DBM, 0.5 mg liver microsomes, 100 mM KH2PO4 (pH 7.4), 5 mM MgCl2, 0.1 mM EDTA,
and a NADPH regeneration system, which consisted of 20 mM
glucose-6-phosphate, 1 unit G-6-P dehydrogenase, 5 mM NADPH in
a final volume of 100 mL. After 5 hr of incubation at 7˚C, the
organic components were extracted and subjected to TLC and HPLC
analysis as described in “MATERIALS AND METHODS”.

somes from Sencar mice fed on a control AIN-76A diet or
1% DBM diet is shown in Figure 2. One major and two
minor peaks were observed in the cases of both control and
1% DBM microsomes after 5 hr of incubation. We have
previously examined the effect of incubation time on the
formation of metabolites by HPLC analysis (data not
shown). It seemed that the major product reached its
maximum quantity after 3 hr and two minors reached the
maximum after longer incubation time in both cases.
Isolation of the major metabolite was performed by silica
gel column chromatography using n-hexane/ethyl acetate
(4/1) as eluent. The fractions were concentrated and
monitored by thin-layer chromatography (TLC). A
colorless liquid corresponding to Rf 0.5 was identified as
the major metabolite of DBM by HPLC analysis. The
structure was deduced by 1 H NMR spectrum as 1,3diphenyl-3-hydroxyl-1-propanone, a reductive form of

DBM (DBMH 2 ), which was further confirmed by
comparing with the synthesized authentic compound. The
NMR spectrum of DBM metabolite clearly showed the
characteristic ABX absorption pattern of β-hydroxyl ketone
moiety, where two methylene protons (C-2a, C-2b) near a
chiral center (C-3) are not chemical shift equivalent and
these three protons are splitted by each other (Jgem = 16 Hz,
J vic = 8.4 Hz and 4.8 Hz). Two conclusions can be
addressed from this finding: (1) The formation of reductive
metabolite that is more polar than DBM will facilitate the
conjugative metabolism by Phase II enzymes and then
excretion; (2) The cytochrome P450-dependent drug metabolism system has been considered consisting of two protein
and a lipid components, cytochrome P450, NADPH
cytochrome P450 reductase and phosphatidylcholine(9).
Therefore, it is reasonable to suggest that DBM may be an
inhibitory factor interferring with the electron supply to the
hemoprotein by accepting electrons directly from the
cytochrome P450 reductase.
II. Identification of Minor Metabolites of DBM by GC-MS
and LC-MS
For further understanding of DBM metabolic pathway
by mouse liver microsomes, the incubation mix was
examined by GC-MS or LC-MS to detect other possible
minor and small molecular metabolites. The identified
structures with their MS spectral information are listed in
Table 1 and their spectra are shown in Figure 3. Several
secondary metabolites of DBM, including chalcone, dihydrochalcone and the oxidative cleaved product, benzoic
acid (further characterized by LC-MS with pseudomolecular ion peak at m/z 123), were identified and the possible
metabolic pathway of DBM by mouse liver microsomes
was proposed (Figure 4). It is worth mentioned that
injection of DBMH2, the primary metabolite of DBM, into
GC-MS resulted in several thermal degradation products,
including benzaldehyde, 1-phenyl-ethanone and traces of
chalcone. Therefore, the identity of chalcone as a metabolite of DBM by liver microsomes in vitro remained questionable and we still cannot tell whether the reduction come
from DBMH 2 directly or from chalcone, the product
resulted from dehydration of DBMH 2. In addition, the
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identification of benzoic acid by LC-MS suggested the
possible important role of oxidative cleaved acid in biochemical and pharmacological aspects in vivo.

The metabolic fate of curcumin in vivo has been
studies back in 1970’s (3) . The major glucuronidated
tetrahydro- and hexahydrocurcumin as well as minor dihy-
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Figures 3. The spectra of identified DBM metabolites. (A) LC-MS of DBMH2 (B) NMR of DBMH2 (C) GC-MS of chalcone (D) GC-MS of
dihydrochalcone.
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Figures 4. Proposed metabolic pathway of DBM by mouse liver microsomes.
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droferulic acid were identified in rat biles. Several possible
routes of reduction has been suggested, including transformation during intestinal absorption(10), gut flora, NADPHlinked α,β-ketoalkene double bond reducatse from rat liver
cytosol(11). However, several studies also suggested that
most of the administered curcumin was reduced by an
endogenous reductase system(12). In our studies, DBM, a
β-diketone analogue of curcumin, was used to demonstrate
that the β -diketone functionality in DBM is reduced
through the action of liver microsomes, in which
cytochrome P450 reductase is thought to be responsible for
the reduction. Therefore, the previous conclusion regarding
the location of the reductive metabolic action on curcumin
needs to be re-considered.
In conclusion, the metabolic fate of DBM by NADPHdependent cytochrome P450 enzymes in mouse liver microsomes was demonstrated. The isolated reductive metabolites of DBM would imply the potential role of DBM as an
inhibitor of cytochrome P450 reductase that is required for
the function of oxidase to metabolize DMBA, resulting in
the inhibitory effect on DMBA-induced mouse mammary
tumorigenesis.
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